Human Vaccines & Immunotherapeutics

metrics 2024

Advancing Immunology Through Groundbreaking Research

Introduction

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

Metrics 2024

SCIMAGO Journal Rank0.93
Journal Impact Factor4.10
Journal Impact Factor (5 years)4.20
H-Index93
Journal IF Without Self4.10
Eigen Factor0.02
Normal Eigen Factor4.00
Influence1.01
Immediacy Index0.90
Cited Half Life4.10
Citing Half Life3.80
JCI0.85
Total Documents5677
WOS Total Citations14391
SCIMAGO Total Citations39510
SCIMAGO SELF Citations3251
Scopus Journal Rank0.93
Cites / Document (2 Years)3.81
Cites / Document (3 Years)3.81
Cites / Document (4 Years)3.85

Metrics History

Rank 2024

Scopus

Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #71/313
Percentile 77.32
Quartile Q1
Immunology and Allergy in Medicine
Rank #69/233
Percentile 70.39
Quartile Q2
Immunology in Immunology and Microbiology
Rank #81/236
Percentile 65.68
Quartile Q2

IF (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 45/174
Percentile 74.40
Quartile Q2
IMMUNOLOGY
Rank 74/181
Percentile 59.40
Quartile Q2

JCI (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 53/174
Percentile 69.54
Quartile Q2
IMMUNOLOGY
Rank 57/181
Percentile 68.51
Quartile Q2

Quartile History

Similar Journals

Med

Bridging Research and Practice for a Healthier Future.
Publisher: CELL PRESSISSN: 2666-6340Frequency: 12 issues/year

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.

MEDICAL MICROBIOLOGY AND IMMUNOLOGY

Driving innovation in the study of microbes and their immune interactions.
Publisher: SPRINGERISSN: 0300-8584Frequency: 6 issues/year

Medical Microbiology and Immunology is a renowned journal published by Springer, serving as a pivotal resource in the fields of microbiology and immunology. Established in 1971 and continuing its legacy through 2024, this journal features cutting-edge research and reviews that address critical advancements and challenges within these dynamic fields. With an impressive impact factor and a robust ranking, including Q1 categories in both Microbiology (medical) and Immunology, it stands at the forefront of scholarly communication, ranking 21st out of 140 in the realm of Medical Microbiology. Researchers and professionals are encouraged to explore a variety of studies that delve into the interactions between microorganisms and the immune system, making it an essential resource for anyone fascinated by these interconnected realms of health sciences. Although not open access, the journal is widely accessible through institutional libraries, ensuring that significant findings reach a global audience. The University of New York Plaza serves as its operational hub in the USA, reinforcing its international influence and dedication to advancing knowledge in microbiology and immunology.

Expert Review of Vaccines

Advancing Global Immunization Through Expert Insights.
Publisher: TAYLOR & FRANCIS LTDISSN: 1476-0584Frequency: 12 issues/year

Expert Review of Vaccines, published by Taylor & Francis Ltd, is a pivotal open access journal that has established itself as a leading source of peer-reviewed articles focusing on vaccine research, development, and policy. With an impressive categorization in the top quartile (Q1) across various domains including Drug Discovery, Immunology, Molecular Medicine, and Pharmacology for 2023, this journal plays a crucial role in disseminating high-quality scientific findings that drive advances in the field. Located in the United Kingdom, it serves a global audience of researchers, healthcare professionals, and students seeking to stay abreast of cutting-edge developments in vaccination strategies and technologies. The journal’s Scopus ranks further attest to its excellence, boasting remarkable placements in Pharmacology and Drug Discovery, reflecting its impact and reach. Since transitioning to an open access format in 2023, the journal has enhanced accessibility to vital research, empowering a broader audience to contribute to and engage with the discourse surrounding vaccines. As the field of immunization continues to evolve, Expert Review of Vaccines remains a cornerstone for those committed to advancing knowledge and practice in this essential area of health science.

BIOLOGICALS

Exploring the intersections of microbiology, biotechnology, and immunology.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1045-1056Frequency: 6 issues/year

BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

ANTIVIRAL RESEARCH

Elevating the Standards of Antiviral Therapy
Publisher: ELSEVIERISSN: 0166-3542Frequency: 12 issues/year

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

INFECTION GENETICS AND EVOLUTION

Unlocking the Secrets of Infection and Adaptation
Publisher: ELSEVIERISSN: 1567-1348Frequency: 8 issues/year

INFECTION GENETICS AND EVOLUTION is a premier scholarly journal published by Elsevier, focusing on the dynamic field of infection genetics and evolutionary biology. Since its inception in 2001, this journal has emerged as a critical platform for the dissemination of cutting-edge research, bridging the gap between molecular genetics, evolutionary theory, and infectious disease study. With an influence profound enough to secure its status in the Q1 category for Ecology, Evolution, Behavior and Systematics and impressive Q2 rankings in Genetics, Infectious Diseases, and Microbiology, the journal offers researchers unparalleled insights that advance the understanding of pathogen evolution and host interactions. Despite the lack of Open Access, the research published in this journal significantly contributes to the academic discourse and informs public health approaches. By publishing high-quality studies and reviews through 2024, INFECTION GENETICS AND EVOLUTION remains indispensable for academics, professionals, and students seeking to explore the intricate mechanisms of infection and adaptation in various organisms.

SEMINARS IN IMMUNOLOGY

Leading the Charge in Immunological Research
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1044-5323Frequency: 6 issues/year

SEMINARS IN IMMUNOLOGY, published by Academic Press Ltd - Elsevier Science Ltd, stands as a leading journal in the field of immunology and allergy, with an impressive impact factor that reflects its significant contribution to advancing research and discourse within these vital areas of medical science. Established in 1989, this esteemed journal has garnered a reputation for disseminating high-quality, peer-reviewed articles that span a broad spectrum of immunological topics, making it an essential resource for researchers, healthcare professionals, and students alike. Currently ranked Q1 in both Immunology and Allergy categories, SEMINARS IN IMMUNOLOGY ranks 39th among 233 journals in Immunology and Allergy and 43rd among 236 in Immunology and Microbiology according to Scopus, placing it in the 83rd and 81st percentiles respectively. This underscores its pivotal role in shaping the future of immunological research and clinical practices. While the journal operates under a subscription model with no open access option, it remains committed to providing comprehensive insights and fostering scholarly collaboration within the global immunology community.

Tuberculosis

Advancing knowledge in the fight against tuberculosis.
Publisher: CHURCHILL LIVINGSTONEISSN: 1472-9792Frequency: 6 issues/year

Tuberculosis is an esteemed peer-reviewed journal specializing in the fields of Infectious Diseases, Immunology, and Microbiology, published by Churchill Livingstone since 1974. With a scope aimed at advancing the understanding and management of tuberculosis and related infectious diseases, the journal provides a platform for innovative research findings, clinical practices, and policy discussions. It is ranked in the Q2 category for both Infectious Diseases and Microbiology (medical), reflecting its significance in the academic community and the impact of its published work. The journal's commitment to openness is evident in its access options, fostering wider dissemination of knowledge. With an impact factor that underscores its relevance, Tuberculosis serves as a crucial resource for researchers, healthcare professionals, and students dedicated to combatting these pressing health challenges. The journal operates from its production headquarters in Edinburgh, Scotland, ensuring a strong connection to the international research community.

npj Vaccines

Empowering Global Immunization Insights
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Vaccines, published by NATURE PORTFOLIO, is an esteemed Open Access journal that has been at the forefront of vaccination research since its inception in 2016. With an impressive impact factor and ranking in the top quartile (Q1) across several categories including Immunology, Infectious Diseases, and Pharmacology, this journal provides a crucial platform for the dissemination of high-quality research and innovative findings in the field of vaccine development. Based in the United Kingdom, and with its broad scope encompassing both fundamental and translational studies, npj Vaccines facilitates significant discourse among researchers, professionals, and students dedicated to immunization strategies and public health. The journal's commitment to Open Access ensures that vital knowledge is shared widely, promoting collaboration and advancement in vaccine science on a global scale. Scholars are encouraged to contribute to this essential field, as their findings may significantly impact the future of disease prevention and control.

IMMUNOLOGIC RESEARCH

Shaping the Future of Health Through Immunological Studies
Publisher: SPRINGERISSN: 0257-277XFrequency: 6 issues/year

IMUNOLOGIC RESEARCH, published by Springer, is a prestigious journal dedicated to advancing the field of immunology. Since its inception in 1986, this journal has provided a vital platform for researchers, practitioners, and students to share groundbreaking studies and innovative findings that influence clinical and laboratory practices in immunology. With an impact factor that reflects its importance, being ranked in the Q2 category for the year 2023 and positioned at 98th out of 236 in Scopus rankings for Immunology, it is recognized among its peers for the quality of its publications. The journal emphasizes rigorous peer review and encourages submissions across a diverse range of topics including but not limited to immune responses, vaccine development, and disease mechanisms. Though it does not currently offer open access, its insightful articles remain crucial for professionals seeking to stay at the forefront of immunological research. Designed for a broad audience within the scientific community, IMMUNOLOGIC RESEARCH continues to foster discovery and discussion that shapes our understanding of immune function and its implications for health and disease.